glucuronyl-glucosamine-glycan-sulfate and Acute-Disease

The aim of the study was to evaluate the clinical efficacy of the association of heparin and sulodexide on experimental pain and on "small sport traumatology". In the experimental part of the study, cutaneous pain threshold and subcutaneous tissue ticking were measured after the induction of an algogenic focus in deep somatic side. In the clinical part of the study, pain intensity (by A.V. scale), athletic performance and therapy duration, in athletes from muscular or articular posttraumatic injuries, were also assessed. After the therapy with the examined drug, a less significant lowering of cutaneous pain threshold and a less subcutaneous tissue thickening were found in the experimental study; in the clinical study a significant reduction of pain intensity and a quick restore of athletic performance were revealed. These results allow to conclude that the drug in effective to reduce painful symptomatology in both experimental and clinical conditions, by the limitation of some aspects of inflammation.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Athletic Injuries; Clinical Trials as Topic; Drug Combinations; Female; Glycosaminoglycans; Heparin; Humans; Male; Middle Aged; Muscles; Pain; Sensory Thresholds

Peritonitis is one of the complications of peritoneal dialysis. We demonstrate the systemic and intraperitoneal anti-inflammatory action of sulodexide given systemically.. Dialysis was performed in male Wistar rats with acute peritonitis induced by addition of endotoxin to the fluid. Sulodexide (10 mg/kg b.w.) was used acutely as supplement to the dialysis fluid or chronically, during 7 days preceding the study by intramuscular (i.m.) injection.. In rats given i.m. sulodexide the dialysate cell count was lower by 45% (p < 0.001) versus untreated rats with peritonitis. Dialysate elastase activity in i.m. sulodexide-treated rats was lower by 22% (p < 0.05) compared to peritonitis. In rats treated with i.m. sulodexide the increase of plasma tumor necrosis factor-alpha was reduced by 53% (p < 0.002). Pretreatment with i.m. sulodexide reduced transperitoneal loss of total protein and albumin during peritonitis by 26% (p < 0.002) and by 16% (p < 0.05), respectively.. Sulodexide given systemically reduces the intraperitoneal and vascular inflammatory response during acute peritonitis in rats.

Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Glycosaminoglycans; Inflammation; Male; Peritoneal Dialysis; Peritonitis; Rats; Rats, Wistar; Treatment Outcome